Chemotherapy-induced alopecia (CIA) is characterized by absent or incomplete hair regrowth after completion of chemotherapy. Alopecia that persists beyond 6 months after completing chemotherapy is defined as persistent chemotherapy-induced alopecia (PCIA). The incidence ranges from […]
The management of androgenetic alopecia (AGA) is evolving. This study updates current prescribing practices compared with 2019–2020. A digital survey was conducted among dermatologists in Spain between March and June 2024, focusing on AGA treatment […]
Background and objective Coronavirus disease 2019 (COVID-19) associated telogen effluvium (CATE) has been observed in patients after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although it is self-limiting, hair loss can be very […]
Low-dose oral minoxidil (≤5mg daily) has emerged as an effective off-label treatment for androgenetic alopecia, outperforming topical minoxidil in terms of adherence. However, the optimal dose has not yet been determined, and high doses may […]
El minoxidil oral a dosis bajas (≤5mg diarios) ha surgido como un tratamiento fuera de indicación efectivo para la alopecia androgenética, superando al minoxidil tópico en términos de adherencia. Sin embargo, la dosis óptima aún […]
The objective of our study was to analyze the effectiveness of oral minoxidil on the frontotemporal hairline in patients with FFA. We conducted a retrospective, descriptive, multicenter study in 2 Brazilian and 1 Spanish centers. […]
El objetivo de nuestro estudio fue analizar la efectividad del minoxidil oral en dosis bajas (LDOM) en la línea del cabello frontotemporal en pacientes con alopecia frontal fibrosante (AFF). Se realizó un estudio retrospectivo, descriptivo […]